|
An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 Clinical research trials and An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2. An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 clinical trial. Human subjects often get the best healthcare available for their An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2 condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2  An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To establish the relationship between the oral dose of zidovudine (AZT) and its hematologic toxicity. AZT has preliminarily been shown to decrease significant events and death in a group of AIDS / Pneumocystis carinii pneumonia (PCP) and AIDS related complex (ARC) patients followed at this time for a limited period. If these data withstand further follow-up, it appears that AZT is a potential antiretroviral agent that may have application in the use of all stages of HIV disease. At this time the optimal dose that will not cause significant toxicity is not known. If this drug has widespread application, it becomes imperative to further study both the dose and the toxicity. Patients with documented HIV viremia and who are well will be evaluated in a dose-escalating protocol for toxicity, persistent viremia, evidence of improvement of immune dysfunction, and the development of further manifestation of HIV disease. Drug levels will be monitored and correlated with the toxicity and viremia.
Details:
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have HIV reactivity. - Patients must belong to one of the following three groups according to the CDC classification: - IIB - including only those patients with autoimmune thrombocytopenia (platelet count = or < 100000 platelets/mm3). - OR Lymphopenia (lymphocyte count = or < 1000 cells/mm3). - OR Helper cell lymphopenia (helper cells < the mean of normals). - OR CDC classification III or IV-C2. - Patients with = or < involuntary 10 percent weight loss in the last 6 months. - ECOG performance status 0 or 1. - Weigh 70 kg + or - 15 kg in order to standardize the g/kg dosing. - Positive antibody for HIV by an ELISA test kit. If the ELISA is negative, then eligibility will be confirmed by second confirmatory test, i.e., immunoblot. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - AIDS or the CDC classification stage IV except stage IV-C2. - HIV antibody negative by immunoblot. - Persistent fevers of > 38.5 degrees C. - Persistent diarrhea undiagnosed > 1 month. - Involuntary weight loss of > 10 percent in the 6 months prior to study entry. - ECOG performance status of 2, 3, or 4. - Class IV-C2 with prior history of: - Multidermal herpes zoster. - Oral candidiasis on more than one occasion. - Tuberculosis. Concurrent Medication: Excluded: - Other antiretroviral agents. - Active immunomodulating agents. - Any other experimental therapy. - Drugs which cause anemia or neutropenia. - Drugs which are glucuronidated and may interfere with the metabolism of AZT, i.e., acetaminophen > 5 days. - Acyclovir systemically administered > 5 days. - Any other experimental agents. Patients with the following are excluded: - AIDS or the CDC classification stage IV except stage IV-C2. - HIV antibody negative by immunoblot. - Persistent fevers of > 38.5 degrees C. - Persistent diarrhea undiagnosed > 1 month. - Involuntary weight loss of > 10 percent in the 6 months prior to study entry. - ECOG performance status of 2, 3, or 4. - Class IV-C2 with prior history of: - Multidermal herpes zoster. - Oral candidiasis on more than one occasion. - Tuberculosis. Prior Medication: Excluded within 3 months of study entry: - Other antiretroviral agents. Active immunomodulating agents. - Excluded within 2 weeks of study entry: - Drugs which cause anemia or neutropenia. - Drugs which are glucuronidated and may interfere with the metabolism of zidovudine (AZT), i.e., acetaminophen > 5 days. - Acyclovir systemically administered > 5 days. - Any other experimental agents. Known active drug abuse.
Total Enrollment:
Location and Contact Information:
Glaxo Wellcome Inc
Research Triangle Park, North Carolina, 27709
United States
Additional Information:
Study ID Numbers: 014C; 013
Study Start Date:
Record last reviewed: February 1995
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002023
Other Hiv Infections Studies:
1. Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
2. The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
3. Effectiveness of Treating HIV-Positive Patients with an HIV Vaccine (Remune)
4. The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients with and without Symptoms of Infection
5. Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients
Related Studies:
Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials
An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
|
|
|
|
|
|
|
|
